Brahma Rasayan

Polyherbal Formulation

Brahma Rasayan is a revered polyherbal Ayurvedic formulation, traditionally used as a rejuvenative tonic (rasayana). It is claimed to enhance mental clarity, memory, and overall well-being, promoting longevity and vitality. This ancient preparation is celebrated for its adaptogenic properties, supposedly helping to balance the doshas (Vata, Pitta, Kapha) and supporting the body's natural restorative processes. It is widely prevalent in Ayurvedic health management.

PLANT FAMILY

Several Families

PARTS USED

Not a plant

AYURVEDIC ACTION

Vata ↓, Pitta ↓, Kapha ↓

ACTIVE COMPOUNDS

Polyherbal (complex mixture)

What is Brahma Rasayan?

Brahma Rasayan is a revered polyherbal Ayurvedic formulation, traditionally used as a rejuvenative tonic. It is a complex blend of numerous herbs, fruits, and other natural ingredients, meticulously prepared according to classical Ayurvedic texts. This ancient preparation is celebrated for its adaptogenic properties, believed to enhance mental clarity, memory, and overall well-being, promoting longevity and vitality.

Its comprehensive composition targets various bodily systems, aiming to balance the doshas and support the body's natural restorative processes. It is often consumed to mitigate stress, improve cognitive function, and bolster immunity, making it a cornerstone in Ayurvedic health management for promoting holistic health.

Other Names of Brahma Rasayan

Brahma Rasayana
Brain Tonic
Immunity Booster
Anti-aging Rasayana

Benefits of Brahma Rasayan

Heading

<h3> Absolute Contraindications of Brahma Rasayan </h3> <h4> Patients on strong immunosuppressive therapy / organ transplant recipients [You are taking powerful immune-suppressing drugs]</h4> <ul> <li>🛑</li> <li>Recommendation: Do not take Brahma Rasayan without transplant team approval; avoid self-administration while on calcineurin inhibitors or other strong immunosuppressants.</li> <li>Reasoning: Brahma Rasayan has been shown in animal studies to raise immune-stimulatory cytokines and enhance leukocyte/bone-marrow activity; this could counteract immunosuppressive regimens or alter drug levels and transplant management.</li> <li>Scientific_Study_Title: Effect of herbal preparation, brahma rasayana, in amelioration of radiation induced damage</li> <li>Scientific_Study_Authors: R. S. Sreekumar, K. P. Guruprasad, et al.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/11324172/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: In mouse models, oral Brahma Rasayan administration (10-50 mg/animal) increased total leukocyte counts, percentage of neutrophils, bone-marrow cellularity and raised serum cytokines including IFN-γ, IL-2 and GM-CSF. The investigators interpreted these findings as stimulation of stem-cell proliferation and cytokine production, effects that supported recovery after radiation injury. Because BR clearly stimulates immune cell numbers and cytokine levels in vivo, there is biologic plausibility that the product could counteract or unpredictably interact with prescribed immunosuppressants used in transplant care.</p> <p>Clinical implication: immunostimulatory activity shown in animals argues for avoidance or close monitoring in patients whose treatment goal is pharmacological immunosuppression.</p> </li> </ul> <h4> Patients undergoing active radiotherapy or certain chemotherapies [You are currently receiving radiation or oxidative-type chemotherapy]</h4> <ul> <li>⚠️</li> <li>Recommendation: Do not self-administer Brahma Rasayan during active radiotherapy or some chemotherapies without explicit oncologist approval; discuss potential risks/benefits with your cancer team.</li> <li>Reasoning: Preclinical work shows BR reduces oxidative damage and supports normal tissue recovery after radiation; while protective effects may reduce side effects, they also raise theoretical concern that antioxidant/radioprotective activity could interfere with tumour-killing mechanisms of radiation or some drugs.</li> <li>Scientific_Study_Title: Effect of brahma rasayana on antioxidant system after radiation</li> <li>Scientific_Study_Authors: K. P. Guruprasad, P. M. Gopinath, et al.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/11906115/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: In irradiated mice, oral Brahma Rasayan (50 mg/animal) restored liver antioxidant enzymes (SOD, CAT) and tissue/serum reduced glutathione reduced by whole-body irradiation; BR also lowered radiation-induced lipid peroxidation. Authors conclude BR ameliorates oxidative damage produced by radiation and may be useful as an adjuvant to radiation therapy. While these tissue-protective benefits are valuable for normal tissue protection, they create a theoretical risk that BR’s antioxidant actions could blunt oxidative mechanisms relied upon to kill tumour cells-hence the clinical caution.</p> </li> </ul> <h4> Concurrent use with oral anticoagulants / strong antiplatelet agents [You take warfarin, rivaroxaban, clopidogrel, aspirin regularly]</h4> <ul> <li>🩸</li> <li>Recommendation: Avoid Brahma Rasayan or consult your prescriber and obtain close INR/bleeding monitoring before starting it if you are on warfarin or similar drugs.</li> <li>Reasoning: Brahma Rasayan formulations commonly include Curcuma (turmeric) and other herbs with antiplatelet or CYP-modulating potential; case reports and mechanistic data tie turmeric/curcumin to altered warfarin effect and possible INR elevation.</li> <li>Scientific_Study_Title: Probable interaction between an oral vitamin K antagonist and turmeric (Curcuma longa)</li> <li>Scientific_Study_Authors: S. A. Bertrand, F. Laroche, et al.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/25230280/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: The authors reported a probable interaction in which co-consumption of turmeric with a vitamin-K antagonist resulted in elevated INR. The case report highlights the need to consider herbal exposures when assessing anticoagulant control. Mechanistic literature shows curcumin can modify CYP activity and platelet function, providing plausible pathways for interaction. Given that Brahma Rasayan often contains turmeric as a classical ingredient, similar interaction risks are credible and warrant monitoring and physician coordination.</p> </li> </ul> <h3> Relative Contraindications of Brahma Rasayan </h3> <h4> Pregnancy and lactation [Pregnant or breastfeeding]</h4> <ul> <li>🤰</li> <li>Recommendation: Avoid Brahma Rasayan during pregnancy and breastfeeding unless a qualified obstetric clinician experienced in herbal medicines advises otherwise.</li> <li>Reasoning: Human safety data in pregnancy are lacking; preclinical genotoxicity and reproductive safety data are limited or animal-specific, so routine avoidance is the conservative choice.</li> <li>Scientific_Study_Title: Studies on Brahma rasayana in male swiss albino mice: Chromosomal aberrations and sperm abnormalities</li> <li>Scientific_Study_Authors: K. P. Guruprasad, Roshan Mascarenhas, P. M. Gopinath, K. Satyamoorthy</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/21829300/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: In an in-vivo mouse study, long-term oral BR did not produce dose-dependent toxicity nor significant chromosomal aberrations or sperm abnormalities; body weight and feed intake were unaffected. While this supports lack of genotoxicity in male mice at tested doses, it does not establish safety in pregnancy or lactation in humans. Because controlled human reproductive safety data are absent, standard clinical prudence recommends avoiding non-essential herbal polyherbal rasayanas during pregnancy and breastfeeding.</p> </li> </ul> <h4> Children (pediatric use) [A child patient]</h4> <ul> <li>🧒</li> <li>Recommendation: Use only under pediatrician or qualified Ayurvedic practitioner guidance; do not give adult doses to children without expert advice.</li> <li>Reasoning: Most controlled clinical data and modern protocols involve adults; pediatric pharmacology, dosing and safety for Brahma Rasayan are not established in robust human trials.</li> <li>Scientific_Study_Title: The clinical evaluation of Basti along with Rasayana on symptoms of post-COVID-19 syndrome: an open-labeled proof of concept pragmatic study - study protocol</li> <li>Scientific_Study_Authors: Amit Nakanekar, Payal Rathod</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/37270514/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: The cited clinical protocol outlines an adult pragmatic trial treating post-COVID-19 adults with a Rasayana regimen that includes Brahma Rasayan for 21 days; the protocol specifies adult participants and careful monitoring of adverse events. The presence of adult-only trial designs and lack of pediatric trial protocols suggests pediatric safety and dosing remain unestablished-hence the recommendation for specialist supervision in children.</p> </li> </ul> <h4> Autoimmune diseases (e.g., uncontrolled lupus, multiple sclerosis) [You have an autoimmune condition]</h4> <ul> <li>🔺</li> <li>Recommendation: Use caution and discuss with your rheumatologist or treating specialist before starting; consider avoiding unless benefit clearly outweighs risk and monitoring is in place.</li> <li>Reasoning: BR increases certain pro-inflammatory and cell-mediated cytokines in animal studies (IFN-γ, IL-2), which theoretically could aggravate autoimmune activity in susceptible patients.</li> <li>Scientific_Study_Title: Effect of Brahma Rasayana on antioxidant systems and cytokine levels in mice during cyclophosphamide administration</li> <li>Scientific_Study_Authors: R. S. Sreekumar, et al.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/11484978/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: In mice given the immunosuppressant cyclophosphamide, co-treatment with BR increased tissue antioxidant enzymes and raised serum cytokines including IFN-γ and IL-2 compared with controls. The authors reported BR enhanced immune markers even in the immunosuppressed state, indicating potent immunomodulatory activity. For people with autoimmune disorders, therapies that increase cell-mediated immunity or cytokine levels could theoretically trigger flares, so individualized risk assessment is advised.</p> </li> </ul>

Heading

<h4> Possible immune activation / worsening of autoimmune symptoms </h4> <ul> <li>🧬</li> <li>Side effect summary: BR can raise immune-active cytokines and blood cell counts in animal studies; this could present as increased inflammation or autoimmune symptom flares in susceptible people.</li> <li>Recommendation: Stop BR and seek medical advice if autoimmune symptoms worsen; discuss with your specialist before starting.</li> <li>Reasoning: Animal studies show increased IFN-γ and IL-2 after BR, consistent with immune stimulation that could aggravate autoimmune disease.</li> <li>Severity Level: Moderate</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Effect of Brahma Rasayana on antioxidant systems and cytokine levels in mice during cyclophosphamide administration</li> <li>Scientific_Study_Authors: R. Sreekumar, K.P. Guruprasad, et al.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/11484978/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: The study in mice found that BR (50 mg/dose) enhanced activities of antioxidant enzymes and increased serum levels of IFN-γ, IL-2 and GM-CSF in both normal and cyclophosphamide-treated animals. These immunostimulatory shifts were significant and reproducible in the model, supporting the mechanistic basis for immune activation after BR administration.</p> </li> </ul> <h4> Increased bleeding risk / altered anticoagulant control</h4> <ul> <li>🩸</li> <li>Side effect summary: Ingredients often present in BR (notably turmeric/curcumin) have been linked to altered warfarin effect and occasional clinically relevant INR elevation or bleeding in case reports.</li> <li>Recommendation: If you are on anticoagulants or have a bleeding disorder, do not take BR without close clinician oversight and INR monitoring.</li> <li>Reasoning: Clinical case reports document INR elevation after turmeric exposure; curcumin can influence drug-metabolizing enzymes and platelet function, creating a bleeding risk when combined with anticoagulants.</li> <li>Severity Level: Severe</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Probable interaction between an oral vitamin K antagonist and turmeric (Curcuma longa)</li> <li>Scientific_Study_Authors: Bertrand S.A., Laroche F., et al.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/25230280/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: The case report describes an apparent herb-drug interaction in which turmeric co-administration was temporally associated with an elevated INR in a patient taking a vitamin-K antagonist. The authors emphasized the need to investigate herbal exposures when unexplained anticoagulant instability occurs. Although single-case reports do not prove causation, they show a plausible clinical signal consistent with known pharmacology of curcuminoids.</p> </li> </ul> <h4> Gastrointestinal upset / dyspepsia (reported anecdotally)</h4> <ul> <li>🤢</li> <li>Side effect summary: Minor GI discomfort or dyspepsia is reported anecdotally with many polyherbal rasayan formulations; robust clinical trial data specifically for BR GI adverse events are limited.</li> <li>Recommendation: Start with a low dose and take with food or warm milk; stop and consult a clinician if persistent GI symptoms occur.</li> <li>Reasoning: Herbal polyherbal formulations can irritate sensitive gastric mucosa or alter digestion in people with low digestive strength (mandagni); reported occurrences are mostly mild and self-limited.</li> <li>Severity Level: Mild</li> <li>Scientific_Study_Available: NA</li> <li>Scientific_Study_Title: NA</li> <li>Scientific_Study_Authors: NA</li> <li>Scientific_Study_Link: NA</li> <li>Scientific_Study_Excerpt: NA</li> </ul>

Heading

<h4> Anticoagulants / Vitamin K antagonists (e.g., warfarin)</h4> <ul> <li>Interaction_Details: Brahma Rasayan commonly includes turmeric/curcumin and other herbs that may alter platelet function or drug metabolism; case reports show possible INR elevation when turmeric is co-used with warfarin.</li> <li>Severity: Severe</li> <li>Recommendation: Avoid concurrent use without close monitoring; if taken, perform frequent INR checks and coordinate with your prescriber.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/25230280/</li> <li>Scientific_Study_Title: Probable interaction between an oral vitamin K antagonist and turmeric (Curcuma longa)</li> <li>Scientfic_Study_Authors: Bertrand S.A., Laroche F., et al.</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: The case report documents an elevation in INR temporally associated with oral turmeric intake in a patient on a vitamin K antagonist. The authors discuss mechanistic possibilities (CYP modulation, effects on vitamin K metabolism or platelet function) and recommend clinicians inquire about herbal intake when anticoagulant control becomes unstable. This single-case observation supports cautious management of BR in patients on warfarin due to shared herbal constituents like curcumin.</p> </li> </ul> <h4> Cytotoxic chemotherapy / Radiotherapy</h4> <ul> <li>Interaction_Details: Brahma Rasayan’s antioxidant and radioprotective actions (documented preclinically) could reduce normal-tissue toxicity but theoretically might also reduce tumor oxidative damage from radiation/oxidative chemotherapies; evidence is mixed and controversial.</li> <li>Severity: Moderate</li> <li>Recommendation: Do not start BR during active chemo- or radiotherapy without oncologist approval; if considered, use only under trial or specialist supervision with outcome monitoring.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/40691411/</li> <li>Scientific_Study_Title: The influence of antioxidant supplementation on adverse effects and tumor interaction during radiotherapy: a systematic review</li> <li>Scientfic_Study_Authors: Julius Limbrunner, Jennifer Doerfler, Klaus Pietschmann, et al.</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: This systematic review examined antioxidant supplementation during radiotherapy and found antioxidants can relieve some radiation side effects (e.g., mucositis), but multiple studies suggest concurrent use may impair tumor control or reduce survival in some contexts. The authors conclude evidence is inconsistent and caution is warranted. Given preclinical data showing BR’s radioprotective and antioxidant actions, concomitant use during active cancer treatment should be managed conservatively with oncology input.</p> </li> </ul> <h4> Calcineurin inhibitors / Tacrolimus (and other CYP3A4-metabolized immunosuppressants)</h4> <ul> <li>Interaction_Details: Components of Brahma Rasayan (for example turmeric/curcumin) can alter CYP3A4 activity; case reports and pharmacokinetic studies indicate turmeric may raise blood levels of tacrolimus and other narrow-therapeutic-index drugs, risking toxicity.</li> <li>Severity: Severe</li> <li>Recommendation: Avoid concurrent use or consult transplant team; if unavoidable, monitor drug levels and renal function closely.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/28104136/</li> <li>Scientific_Study_Title: Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report</li> <li>Scientfic_Study_Authors: K. Oba, et al.</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: A clinical case reported a liver-transplant recipient who developed acute nephrotoxicity with a marked rise in tacrolimus levels after consuming high amounts of turmeric; tacrolimus levels subsequently fell when turmeric was stopped. The authors highlight turmeric’s potential to inhibit drug metabolism (CYP3A4) and thereby increase calcineurin inhibitor levels, which can cause serious nephrotoxicity-supporting caution with BR in transplant recipients or others on tacrolimus.</p> </li> </ul> <h4> Drugs metabolized by CYP3A4 / CYP1A2 (general interactions via curcumin)</h4> <ul> <li>Interaction_Details: Curcumin (present in many BR preparations) can inhibit CYP3A and CYP1A2 in vitro; co-administration may increase blood levels of drugs cleared by these enzymes (statins, some anticancer agents, certain anticonvulsants, etc.).</li> <li>Severity: Moderate</li> <li>Recommendation: Consult your prescribing clinician before combining BR with drugs having narrow therapeutic windows that are primarily CYP3A4/1A2 substrates; consider therapeutic drug monitoring where available.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35695287/</li> <li>Scientific_Study_Title: Curcumin and quercetin modify warfarin-induced regulation of porcine CYP1A2 and CYP3A expression and activity in vitro</li> <li>Scientfic_Study_Authors: L. R. Terracciano, et al.</li> <li>Scientific_Study_Excerpt: <p>Paraphrase: In vitro hepatocyte and microsomal studies showed curcumin inhibited CYP1A2 and CYP3A activities and altered expression induced by warfarin. These findings demonstrate curcumin’s capacity to modulate major drug-metabolizing enzymes and support a biologic rationale for herb-drug interactions with medications that are CYP substrates. While in vitro results do not always predict clinical magnitude, they provide mechanistic basis to monitor for interactions when BR (containing curcumin) is used with CYP-metabolized drugs.</p> </li> </ul>